Protagonist Therapeutics (PTGX) Operating Leases (2019 - 2025)
Protagonist Therapeutics (PTGX) has disclosed Operating Leases for 7 consecutive years, with $8.0 million as the latest value for Q4 2025.
- Quarterly Operating Leases fell 22.36% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, down 22.36% year-over-year, with the annual reading at $8.0 million for FY2025, 22.36% down from the prior year.
- Operating Leases hit $8.0 million in Q4 2025 for Protagonist Therapeutics, down from $8.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $11.0 million in Q2 2024 to a low of $462000.0 in Q1 2023.
- Historically, Operating Leases has averaged $5.8 million across 5 years, with a median of $4.2 million in 2021.
- Biggest five-year swings in Operating Leases: dropped 13.24% in 2021 and later plummeted 84.91% in 2023.
- Year by year, Operating Leases stood at $3.7 million in 2021, then crashed by 68.81% to $1.1 million in 2022, then tumbled by 59.51% to $462000.0 in 2023, then skyrocketed by 2141.56% to $10.4 million in 2024, then dropped by 22.36% to $8.0 million in 2025.
- Business Quant data shows Operating Leases for PTGX at $8.0 million in Q4 2025, $8.5 million in Q3 2025, and $9.1 million in Q2 2025.